Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTC-352 in metastatic ER+ breast cancer
NCT03201913Phase 1Completed
- Sponsor
- TTC Oncology
- Start
- Dec 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TTC-352 in breast cancer, sponsored by TTC Oncology. Primary endpoint: Maximum Tolerated Dose at 24 months. Started Dec 2017; status: completed.
02
Drugs
TTC-352
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03201913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201913.